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Abstract: To identify susceptibility variants for hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC), we conducted a gen-
ome-wide association study by genotyping 440,794 SNPs in 355
chronic HBV carriers with HCC and 360 chronic HBV carriers without
HCC, all of Chinese ancestry. We identiﬁed one intronic SNP
(rs17401966) in KIF1B on chromosome 1p36.22 that was highly
associated with HBV-related HCC and conﬁrmed this association in
ﬁve additional independent samples, consisting of 1962 individuals
with HCC, 1430 control subjects, and 159 family trios. Across the
six studies, the association with rs17401966 was highly statistically
signiﬁcant (joint odds ratio = 0.61, P = 1.7  10(18)). In addition
to KIF1B, the association region tagged two other plausible causative
genes, UBE4B and PGD. Our ﬁndings provide evidence that the
1p36.22 locus confers susceptibility to HBV-related HCC, and suggest
that KIF1B-, UBE4B-, or PGD-related pathways might be involved in
the pathogenesis of this malignancy.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.
Hepatocellular carcinoma (HCC) is the third most deadly and ﬁfth
most common cancer worldwide. The majority of HCC cases
occur in China. The etiology of liver cancer is known with risk fac-
tors including hepatitis B virus (HBV), hepatitis C virus (HCV), cir-
rhosis, gender, diabetes, obesity, alcohol, and smoking, all whichJournal of Hepatology 20
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While over 80% of HCC occurs in the background of inﬂammation,
mainly caused by viral hepatitis [1] only a fraction of patients
with CLD develop HCC, suggesting that the individual genetic
background contributes to HCC risk. Patients with HCC currently
have a very poor outcome, partly due to the advanced stages of
disease at clinical presentation and to its heterogeneity. HCC
prognosis is also complicated by both the tumor stage and the
condition of the liver when compromised by hepatitis virus, mak-
ing it difﬁcult to provide clinical recommendations. At this time,
only 10–20% of HCC patients are eligible for potentially curative
therapies, such as resection and liver transplantation. However,
many patients have a propensity to develop post-surgical recur-
rence [2]. Thus, the identiﬁcation of genetic susceptibility loci
and the development of new biomarkers and stratiﬁcation pro-
grams based on these loci are needed to reﬁne diagnosis and
improve patient outcome.
There are a few studies that have utilized a candidate
approach to select promising genes carrying single nucleotide
polymorphisms (SNP) and attempted to link these genetic com-
ponents to HCC susceptibility and/or prognosis [3,4]. These types
of studies are limited due to their cohort-speciﬁc nature and to a
design which produces high false positive data requiring addi-
tional independent validation. Recently, genome-wide associa-
tion studies (GWAS) have been utilized to perform large-scale
interrogation of genetic variants in cancer. While these studies
have identiﬁed susceptibility loci for common cancers types, such
as breast and prostate, a GWAS for liver cancer has been lacking.
In their recent work, Zhang and colleagues have conducted
the ﬁrst liver GWAS for HCC in chronic HBV carriers of Chinese
ancestry [5]. Using the Affymetrix Genome-Wide Human SNP
Array 5.0 to assess 355 HBV HCC cases and 360 HBV controls,
they identiﬁed rs17401966, as a new susceptibility SNP, located
on chromosome 1p36.22, for HBV-related HCC. As described in
their manuscript, the association of this intronic SNP with HBV-
related HCC was conﬁrmed in ﬁve additional replication cohorts
(joint odds ratio = 0.61, p = 1.7  1018). This study is timely and
important to the ﬁeld of HCC research. It provides a good exam-
ple of mobilizing resources and bringing clinicians, basic
researchers, and statisticians together towards a collaborative
effort. The authors are congratulated on effectively managing a
complicated study and addressing this difﬁcult disease with a
global health impact.
Although the ﬁndings from this study are of importance to the
ﬁeld of liver cancer and to the cancer GWAS efforts as a whole,11 vol. 54 j 823–824
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the initial study by Zhang et al. is underpowered, and, given this
fact, remarkably produced an SNP of interest. However,
rs17401966 only had a statistical level of 106 in the initial
GWAS scan which, as noted in the literature and by the authors,
is below what is considered to be genome-wide signiﬁcance
(p <107), a cutoff level which takes multiple testing into account.
Therefore, the choice to move forward with replication of this
SNP in additional cohorts is debatable and worrisome. With this
in mind, this SNP did not reach signiﬁcance in unadjusted condi-
tions in any of the ﬁve case-control studies or family trios used in
the follow-up studies. It is not surprising therefore, that associa-
tions were not found between the SNPs identiﬁed in this HCC
study and other SNPs of interest found in other GWAS. The seem-
ingly ‘cherry-picking’ approach of selecting this SNP raises the
question of whether this study should be considered a GWAS
approach since the selection of this SNP was not based on a global
unbiased rule. In addition, based on the results shown in Table 2
of the Zhang manuscript, rs17401966 was the third ranking SNP
in the initial scan and it would be interesting to see how the top
two SNPs fared in the replication and pooled studies.
GWAS-based statistical signiﬁcance of rs17401966 was met
upon pooling the data of these cohorts; however, the pooled
cohorts were recruited from different regions of China with dif-
fering eligibility, recruitment, and enrollment criteria and repre-
sent un-matched sample sets. It would therefore be of interest to
determine whether ethnic and clinical parameter differences are
represented within the pooled dataset. This also becomes an
issue since pooled samples were used in stratiﬁcation analyses
based on age and gender. It is also unclear whether the multiple
cohorts used in this study represent a selected population of
cases since the majority of cases were hospital-based. The
authors also genotyped rs17401966 in two control populations,
one of which contained patients with no HBV and the other
where HBV infection status was unknown and found a similar
frequency of the rs17401966[G] allele between these control
groups and chronic HBV carriers. However, it is unclear, whether
this analysis was performed with the HBV carriers from the initial
scan or from the pooled data. Regardless, an analysis of odds ratio
between the population controls and the HBV carriers or HCC
cases was not presented in this study and would shed some light
on the relevance of HBV infection to their ﬁndings.
While the ﬁndings of this HCC GWAS are of interest to the
ﬁeld, several factors noted above impede the interpretation of
the results. Therefore, we recommend the following in future
liver GWAS: (1) An appropriate sample size is needed to ensure824 Journal of Hepatology 201sufﬁcient power to identify signiﬁcant GWAS SNPs. (2) Since
allele frequency can differ among subgroups and populations,
a concerted effort should be made to design studies in uniform
ethnic groups. (3) Since each of the several etiologies that
underlie HCC can individually contribute to disease onset and
progression, GWAS should be constructed to speciﬁcally
address each etiological type. Thus, we advocate that amply
powered GWAS should be conducted in homogeneous popula-
tions that are well-matched and address the effect of a single
variable on the association of a SNP with disease incidence
and/or outcome.
Our ability to assess liver cancer and, importantly, to identify
new biomarkers for diagnosis, prognosis, and prediction has
recently been expanded by the growing ﬁeld of knowledge based
on high-throughput genomics. While many cancer types have
also been interrogated for genetic alterations by candidate-gene
studies and GWAS, the liver cancer arena has lacked much of this
information. While recent endeavors, such as those described in
Zhang et al., have raised the bar, much effort is still needed to
ensure that GWAS are well-designed and well-powered to
achieve robust results which can be applied to improve the care
of patients suffering from this disease.Conﬂict of interest
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